SG Americas Securities LLC Purchases 45,430 Shares of Cryoport, Inc. (NASDAQ:CYRX)

SG Americas Securities LLC boosted its holdings in shares of Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 44.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 146,789 shares of the company's stock after buying an additional 45,430 shares during the quarter. SG Americas Securities LLC owned approximately 0.30% of Cryoport worth $1,142,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Hsbc Holdings PLC acquired a new position in shares of Cryoport during the 2nd quarter worth approximately $92,000. XTX Topco Ltd bought a new position in Cryoport during the second quarter worth $198,000. Marshall Wace LLP acquired a new position in shares of Cryoport in the second quarter valued at $282,000. Cubist Systematic Strategies LLC bought a new position in shares of Cryoport in the second quarter valued at about $378,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Cryoport during the 2nd quarter worth about $355,000. Institutional investors own 92.90% of the company's stock.

Cryoport Trading Down 2.4 %

CYRX traded down $0.19 during trading on Friday, reaching $7.55. 176,400 shares of the company's stock were exchanged, compared to its average volume of 267,721. The firm has a fifty day moving average price of $7.83 and a two-hundred day moving average price of $7.96. The stock has a market capitalization of $372.95 million, a PE ratio of -2.23 and a beta of 1.58. Cryoport, Inc. has a one year low of $5.32 and a one year high of $20.10. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48.

Cryoport (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.23. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The company had revenue of $56.66 million for the quarter, compared to analyst estimates of $58.13 million. During the same period in the prior year, the firm posted ($0.31) EPS. As a group, equities research analysts forecast that Cryoport, Inc. will post -0.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Ramkumar Mandalam sold 7,369 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $7.46, for a total transaction of $54,972.74. Following the transaction, the director now owns 59,497 shares of the company's stock, valued at $443,847.62. This represents a 11.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jerrell Shelton sold 50,000 shares of the business's stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the sale, the chief executive officer now directly owns 731,897 shares of the company's stock, valued at $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,869 shares of company stock worth $735,673. Company insiders own 10.10% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on CYRX shares. UBS Group upped their price target on shares of Cryoport from $7.00 to $9.00 and gave the company a "neutral" rating in a research note on Friday, October 18th. Roth Mkm cut their price target on Cryoport from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, November 8th. Guggenheim initiated coverage on shares of Cryoport in a research report on Thursday, December 19th. They set a "buy" rating and a $11.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 target price on shares of Cryoport in a report on Friday, January 17th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $12.29.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.